Remote Targets for Right Coronary Artery Bypass: Distal Trunk or Posterior Descending Artery Grafting

Abstract

Background Choosing a good anastomotic site is crucial during surgical revascularization of the right coronary artery (RCA) system. In many instances of distal and/or sequential main trunk disease, either the right posterior descending coronary artery (RPDA) or distal part of the right main coronary artery (DRCA) is preferred as the target vessel. In this article, the saphenous vein graft (SVG) patency is compared between these two main targets in the long term.

Materials and Methods Postoperative control coronary angiograms were obtained and assessed from 452 patients undergoing conventional on-pump coronary artery bypass grafting with either a DRCA (n = 305) or a RPDA graft (n = 147) after an average postoperative period of 5.8 ± 4.3 years (range: 2 months–20 years; a total of 2,627 patient-years).

Results The overall graft patency was 60%. The 15-year patency rate was better for the DRCA grafts than that for the RPDA grafts (32 ± 5% vs. 19 ± 6%, respectively; p = 0.001), irrespective of target vessel caliber. Other factors adversely influencing the long-term graft patency were poor target vessel quality (p = 0.002) and hypercholesterolemia (p = 0.01). On the other hand, target vessel diameter, diabetes mellitus, hypertension, chronic renal insufficiency, obesity, peripheral arterial disease, or SVG quality were not associated with poor long-term graft patency in these patients having distal-type RCA disease.

Conclusions In the presence of distal and/or sequential right coronary disease, DRCA may be the target vessel of choice for bypass grafting, rather than the RPDA, mainly for better long-term SVG patency rates in this location.

Keywords

coronary artery bypass grafts surgery - CABG - atherosclerosis - restenosis

• References

• 1 Vural KM, Sener E, Taşdemir O. Long-term patency of sequential and individual saphenous vein coronary bypass grafts. Eur J Cardiothorac Surg 2001; 19 (2) 140-144
• 2 Vural KM, Iscan ZH, Kunt A, Sener E, Tasdemir O. Off-pump, in situ internal thoracic artery grafting: a durable treatment for single-vessel coronary artery disease. Ann Thorac Surg 2005; 79 (3) 814-818
• 3 Vural KM, Iscan ZH, Kunt A, Sener E, Tasdemir O. Off-pump coronary artery bypass grafting: long term angiographic results. J Card Surg 2005; 20 (2) 153-159
• 4 Shah PJ, Gordon I, Fuller J , et al. Factors affecting saphenous vein graft patency: clinical and angiographic study in 1402 symptomatic patients operated on between 1977 and 1999. J Thorac Cardiovasc Surg 2003; 126 (6) 1972-1977
• 5 Roth JA, Cukingnan RA, Brown BG, Gocka E, Carey JS. Factors influencing patency of saphenous vein grafts. Ann Thorac Surg 1979; 28 (2) 176-183
• 6 Fitzgibbon GM, Kafka HP, Leach AJ, Keon WJ, Hooper GD, Burton JR. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol 1996; 28 (3) 616-626
• 7 Tatoulis J, Buxton BF, Fuller JA. The right internal thoracic artery: the forgotten conduit—5,766 patients and 991 angiograms. Ann Thorac Surg 2011; 92 (1) 9-15 , discussion 15–17
• 8 Dion R, Glineur D, Derouck D , et al. Complementary saphenous grafting: long-term follow-up. J Thorac Cardiovasc Surg 2001; 122 (2) 296-304
• 9 Campeau L, Enjalbert M, Lespérance J , et al. The relation of risk factors to the development of atherosclerosis in saphenous-vein bypass grafts and the progression of disease in the native circulation. A study 10 years after aortocoronary bypass surgery. N Engl J Med 1984; 311 (21) 1329-1332
• 10 Kim FY, Marhefka G, Ruggiero NJ, Adams S, Whellan DJ. Saphenous vein graft disease: review of pathophysiology, prevention, and treatment. Cardiol Rev 2013; 21 (2) 101-109
• 11 Kay PH, Brooks N, Magee P, Sturridge MF, Walesby RK, Wright JE. Bypass grafting to the right coronary artery with and without endarterectomy: patency at one year. Br Heart J 1985; 54 (5) 489-494
• 12 Goldman S, Copeland J, Moritz T , et al. Saphenous vein graft patency 1.  year after coronary artery bypass surgery and effects of antiplatelet therapy. Results of a Veterans Administration Cooperative Study. Circulation 1989; 80 (5) 1190-1197
• 13 Ng CS, Wan S. Limiting inflammatory response to cardiopulmonary bypass: pharmaceutical strategies. Curr Opin Pharmacol 2012; 12 (2) 155-159
• 14 Kulik A, Voisine P, Mathieu P , et al. Statin therapy and saphenous vein graft disease after coronary bypass surgery: analysis from the CASCADE randomized trial. Ann Thorac Surg 2011; 92 (4) 1284-1290 , discussion 1290–1291
• 15 Buxton BF, Durairaj M, Hare DL , et al. Do angiographic results from symptom-directed studies reflect true graft patency?. Ann Thorac Surg 2005; 80 (3) 896-900 , discussion 900–901
• 16 Grunkemeier GL, Wu Y. Actual versus actuarial event-free percentages. Ann Thorac Surg 2001; 72 (3) 677-678